A5073814876- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Immune Response and Inflammation
- Nanowire Synthesis and Applications
- Neonatal and Maternal Infections
- Galectins and Cancer Biology
- Cancer Immunotherapy and Biomarkers
- Immunodeficiency and Autoimmune Disorders
- Immune cells in cancer
- Protein Tyrosine Phosphatases
- Whipple's Disease and Interleukins
- Streptococcal Infections and Treatments
- Advancements in Semiconductor Devices and Circuit Design
- RNA Interference and Gene Delivery
Allen Institute
2018-2021
Massachusetts Institute of Technology
2019-2021
Koch Institute for Integrative Cancer Research At MIT
2021
University of Chicago
2014-2016
Chimeric antigen receptor-T cell (CAR-T) therapy has been effective in the treatment of hematologic malignancies, but it shown limited efficacy against solid tumors. Here we demonstrate an approach to enhancing CAR-T function tumors by directly vaccine-boosting donor cells through their chimeric receptor vivo. We designed amphiphile ligands (amph-ligands) that, upon injection, trafficked lymph nodes and decorated surfaces antigen-presenting cells, thereby priming CAR-Ts native node...
Abstract Antitumor T-cell responses have the potential to be curative in cancer patients, but induction of potent immunity through vaccination remains a largely unmet goal immunotherapy. We previously reported that immunogenicity peptide vaccines could increased by maximizing delivery lymph nodes (LNs), where are generated. This was achieved conjugating 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-PEG (DSPE-PEG) promote albumin binding, which resulted enhanced lymphatic drainage and...
Abstract SHP2 is a ubiquitous tyrosine phosphatase involved in regulating both tumor and immune cell signaling. In this study, we discovered novel modulatory function of SHP2. Targeting protein with allosteric inhibitors promoted anti-tumor immunity, including enhancing T cytotoxic immune-mediated regression. Knockout using CRISPR/Cas9 gene editing showed that targeting cancer cells contributes to response. Inhibition activity augmented intrinsic IFNγ signaling resulting enhanced...
Inducing a strong and specific immune response is the hallmark of successful vaccine. Nanoparticles have emerged as promising vaccine delivery devices to discover elicit responses. Fine-tuning nanoparticle create an with antibody other cellular responses influenced by many factors such shape, size, composition. Peptide amphiphile micelles are unique biomaterials platform that can function modular system, enabling control over these important delivering payloads more efficiently draining...
Treatments aiming to augment immune checkpoint blockade (ICB) in cancer often focus on T cell immunity, but innate cells may have important roles play. Here, we demonstrate a single-dose combination treatment (termed AIP) using pan-tumor-targeting antibody surrogate, half-life-extended interleukin-2 (IL-2), and anti-programmed death 1 (PD-1), which primes tumors respond subsequent ICB promotes rejection of large established mice. Natural killer (NK) macrophages activated by AIP underwent...
Treatments aiming to augment immune checkpoint blockade (ICB) in cancer often focus on T cell immunity, but innate cells may have important roles play. Here we demonstrate a single-dose combination treatment (termed AIP) employing pan-tumor-targeting antibody surrogate, half-life-extended interleukin-2 (IL-2), and anti-PD-1, which primes tumors respond subsequent ICB promotes rejection of large established mice. NK macrophages activated by AIP underwent transcriptional reprogramming, rapidly...